Methylene Blue
- 1 September 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 37 (9) , 474-477
Abstract
Methylene blue has been in medicinal use for centuries and is best known as an antidotal treatment for acquired methemoglobinemia (MetHB). More recently, methylene blue has gained recognition for its efficacious use in the treatment of ifosfamide neurotoxicity and refractory vasoplegic shock in both the pediatric and adult critical care literature, extending its use beyond MetHB. Methylene blue’s mechanism of action is somewhat complex and based partly on its oxidizing capabilities, ironically the same mechanism that causes MetHB. This review will examine methylene blue’s use in the treatment of acquired MetHB and ifosfamide neurotoxicity and review the current literature regarding its role in critically ill pediatric and adult patients with refractory vasoplegic shock. Methylene blue’s pharmacologic actions, dosing, and adverse effects will also be discussed.Keywords
This publication has 13 references indexed in Scilit:
- Methylene Blue for Refractory Shock in Children: A Systematic Review and Survey Practice AnalysisPediatric Critical Care Medicine, 2020
- Intraoperative vasoplegiaCurrent Opinion in Anaesthesiology, 2018
- Methylene BlueAnesthesia & Analgesia, 2016
- A Novel Use of Methylene Blue in the Pediatric ICUPediatrics, 2015
- Improvement in Hemodynamics After Methylene Blue Administration in Drug-Induced Vasodilatory Shock: A Case ReportJournal of Medical Toxicology, 2015
- Methylene blue used in the treatment of refractory shock resulting from drug poisoningClinical Toxicology, 2013
- Methylene Blue for Distributive Shock: A Potential New Use of an Old AntidoteJournal of Medical Toxicology, 2013
- Use of Methylene Blue in Sepsis: A Systematic ReviewJournal of Intensive Care Medicine, 2006
- Methylene Blue for Management of Ifosfamide-Induced EncephalopathyAnnals of Pharmacotherapy, 2006
- Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literatureBritish Journal of Cancer, 2000